Mark Baldry - 16 May 2025 Form 4/A - Amendment Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Chief Commercial Officer
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Issuer symbol
XFOR
Transactions as of
16 May 2025
Net transactions value
+$2,561
Form type
4/A - Amendment
Filing time
03 Jun 2025, 17:01:06 UTC
Date Of Original Report
20 May 2025
Previous filing
27 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Baldry Mark Chief Commercial Officer C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON /s/ Adam S. Mostafa, attorney-in-fact 03 Jun 2025 0001644137

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XFOR Common Stock Award $2,561 +1,032 +4.2% $2.48 25,337 16 May 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share. Such transaction was exempt under both Rule 16b-3(d) and Rule 16b-3(c) of the Securities Exchange Act of 1934, as amended.

Remarks:

On May 20, 2025, a Form 4 was filed on behalf of the Reporting Person which inadvertently reported a transaction that occurred on May 16, 2025 using the incorrect transaction code P in Column 3 of Table I. As shown in this amendment, this transaction is reported using transaction code A in Column 3 of Table I.